You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Alkontrol herbal for Treating Alcohol Abuse

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: NIAAA

    DESCRIPTION provided by applicant This application for a Fast Track STTR award represents a collaboration between Natural Pharmacia International Inc NPI and McLean Hospital to initiate steps toward commercializing a isoflavone botanical product for treating alcoholism Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of PAR Pepducins for the Treatment of Atopic Dermatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant Atopic dermatitis AD or severe eczema is a very common life long skin disease with of adults in the US requiring systemic therapy Clinical manifestations of AD include multiple inflamed lesions erosions accompanied by lichenification thick leathery skin fibrotic papules and severely dry skin with increased susceptibility to infection A major uncont ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Purging Latent HIV Reservoirs through a Combination HIV Therapeutic

    SBC: APHIOS CORPORATION            Topic: NIAID

    PROJECT SUMMARY We hypothesize that Protein Kinase C PKC agonists such as the non tumorigenic Bryoids combined with HDAC inhibitors HDACi represent a valuable pharmacological approach to purge latent HIV from cellular reservoirs We also hypothesize that a combination of a Bryoid and an HDACi co encapsulated in a long circulation pegylated immunonanosomes coated with anti PD L nanobodies w ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. An Oral Long-Acting Doxycycline for Onchocerciasis Eradication: Process Improvement for Small Batch Manufacturing

    SBC: Lyndra Therapeutics, Inc.            Topic: NIAID

    An Oral Long Acting Doxycycline for Onchocerciasis Eradication Process Improvement for Small Batch Manufacturing Project Summary Patients with Onchocerciasis African River Blindness are currently treated with microfilaricidal therapies such as ivermectin To achieve Onchocerciasis eradication however will require addition of a macrofilaricidal to current mass drug administration campaigns Do ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. iMedPAL: Improving Medical Prescription Adherence by Leveraging Mobile Technology

    SBC: VIVONICS INC            Topic: NIAID

    DESCRIPTION provided by applicant In the US there are over pediatric recipients of organs every year To prevent organ rejection these patients must strictly adhere to treatment programs that require a combination of immunosuppressants and steroids that must be taken throughout the day and must be taken for the rest of their lives Adolescence is a time period when patients are often t ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Development of immuno-PET agents for the selective imaging of CD8 T cells

    SBC: Agenus Inc.            Topic: 102

    Project summary Therapeutic strategies that seek to stimulate adaptive immunity for the treatment of cancer have recently shown convincing clinical efficacy Immune checkpoint inhibitors CPIs for example reactivate a patient s own T cells to eliminate tumors by blocking interactions that cause tumor infiltrating lymphocytes TILs to become exhausted CPIs have demonstrated remarkable success ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. A Library of Immunoaffinity Reagents for RNA modifications

    SBC: VISTERRA, INC.            Topic: NIDA

    Project Abstract While there are commercial monoclonal antibodies against several RNA modifications there is a general paucity of immunological tools for the andgt known RNA modifications This lack of immunological tools is hindering study of the emerging roles for modified ribonucleosides as critical players in the many basic cell and organismal processes in viruses bacteria parasites and ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. A technology solution for peer-led Seeking Safety

    SBC: LMN CONSULTING            Topic: NIDA

    DESCRIPTION provided by applicant Peers are increasingly recognized as an important asset in healthcare Peer supports are historically most prominent for substance use disorder SUD For trauma and posttraumatic stress disorder PTSD there have been very few attempts at peer help A key challenge of trauma peer groups is that they usually focus on andquot telling the storyandquot of member ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Marijuana Breath Analyzer

    SBC: GINER INC            Topic: NIDA

    PROJECT SUMMARY ABSTRACT Marijuana Breath Analyzer Enforcement of drugged driving laws has attracted significant attention due to increase in drug related incidents and the decriminalization and legalization of marijuana in some states Studies have shown that marijuana use can impair a driverandapos s judgment Next to alcohol marijuana is the second most frequently found substance in the bodie ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Targeted Antimicrobial Treatment of Acne Vulgaris with a novel class of Enzybiotics from Mycobacteriophage lysterases

    SBC: Dermalytica Inc.            Topic: NIAMS

    Acne is the most common dermatological condition that affects close to of the years old cohort with varying degrees of severity and can cause significant psychosocial issues that can be debilitating for the patients There is a large unmet medical need in acne treatments because of the increasing prevalence of antibiotic resistant bacteria and the significant side effects of current tre ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government